King discontinues Cortisporin otic suspension
King Pharmaceuticals has discontinued the manufacture of Cortisporin otic suspension (neomycin/polymyxin B sulfates/hydrocortisone). This decision is based upon many factors, including the company's understanding of current medical therapy and the availability of alternative therapies.
Cortisporin otic suspension is indicated for the treatment of susceptible bacterial infections of the external auditory canal, mastoidectomy and fenestration cavities.
For more information call (800) 776-3637 or visit www.fda.gov/cder/drug/shortages/default.htm#CortisporinOtic.